<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092750</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0479</org_study_id>
    <nct_id>NCT05092750</nct_id>
  </id_info>
  <brief_title>Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer</brief_title>
  <official_title>Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the feasibility of Sentinel Lymph Node (SLN) mapping using novel magnetic&#xD;
      tracers (FerroTrace) and indocyanine green (ICG) for colorectal cancer; and to evaluate&#xD;
      safety by assessing short term toxicity associated with colonoscopic peritumoral injection of&#xD;
      novel magnetic nanoparticles (FerroTrace) and ICG for colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY:&#xD;
&#xD;
        1. To determine the feasibility of Sentinel Lymph Node (SLN) mapping using novel magnetic&#xD;
           tracers (FerroTrace) and indocyanine green (ICG) for colorectal cancer.&#xD;
&#xD;
        2. To evaluate safety by assessing short term toxicity associated with colonoscopic&#xD;
           peritumoral injection of novel magnetic nanoparticles (FerroTrace) and ICG for&#xD;
           colorectal cancer.&#xD;
&#xD;
      SECONDARY:&#xD;
&#xD;
      1. To determine the additional positive diagnostic value of adding sentinel lymph node&#xD;
      mapping to lymphadenectomy by assessing the SLNs with detailed immunochemistry versus the&#xD;
      normal H&amp;E staining pathology tests.&#xD;
&#xD;
      PRIMARY END POINTS:&#xD;
&#xD;
        1. Feasibility: Number of registered patients who complete all study procedures with at&#xD;
           least one sentinel node identified.&#xD;
&#xD;
        2. Safety: Rate of any grade III or greater toxicity attributable to FerroTrace injection,&#xD;
           evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0.&#xD;
           Adverse events according to general peri-operative complications.&#xD;
&#xD;
      SECONDARY ENDPOINTS:&#xD;
&#xD;
        1. The identification rate and number of FerroTrace-positive lymph nodes for each patient.&#xD;
&#xD;
        2. Incidence of pathological upstaging of LN metastasis status by the addition of&#xD;
           (non-routine) serial H&amp;E and immunohistochemistry in the pathological assessment of&#xD;
           identified FerroTrace-positive lymph nodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FerroTraceTM (magnetic tracer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FerroTraceTM</intervention_name>
    <description>A magnetic</description>
    <arm_group_label>FerroTraceTM (magnetic tracer)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green (ICG)</intervention_name>
    <description>Given by SC injection</description>
    <arm_group_label>FerroTraceTM (magnetic tracer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Willing to provide informed consent&#xD;
&#xD;
          -  Biopsy proven colon or rectal cancer&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Serious medical comorbidities or other contraindications to surgery +/- adjuvant&#xD;
             therapy as determined by the treatment team&#xD;
&#xD;
          -  Previous pelvic radiotherapy or radiotherapy planned prior to surgery&#xD;
&#xD;
          -  Allergy or intolerance to iron oxide compounds&#xD;
&#xD;
          -  Iron overload disorder&#xD;
&#xD;
          -  Allergy or intolerance to iodides&#xD;
&#xD;
          -  Pregnant or lactating women*&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Tillman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Tillman</last_name>
    <phone>(713) 745-4327</phone>
    <email>mmtillman@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Tillman</last_name>
      <phone>713-745-4327</phone>
      <email>mmtillman@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Tillman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

